Payment overview · 2025
General Payments
$13.76
1 reported records · 1 companies
Healthcare provider profile · identity verified
Charles Jay Vandenberg, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MANISTEE, MI · NPI 1750638516
Verified facts
What the public records show
CMS Open Payments records show Charles Jay Vandenberg, D.O. received $13.76 in general payments during 2025 across 1 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 606 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 123 |
| Lisinopril | Lisinopril | 426 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 379 | 73 |
| Omeprazole | Omeprazole | 347 | 103 |
| Gabapentin | Gabapentin | 320 | 65 |
| Losartan Potassium | Losartan Potassium | 313 | 83 |
| Simvastatin | Simvastatin | 299 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 64 |
| Eliquis | Apixaban | 245 | 49 |
| Celecoxib | Celecoxib | 241 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 65 |
| Furosemide | Furosemide | 194 | 54 |
| Alprazolam | Alprazolam | 187 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 50 |
| Trazodone Hcl | Trazodone Hcl | 181 | 52 |
| Meloxicam | Meloxicam | 176 | 62 |
| Metformin Hcl | Metformin Hcl | 166 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 60 |
| Montelukast Sodium | Montelukast Sodium | 151 | 38 |
| Tramadol Hcl | Tramadol Hcl | 150 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 31 |
| Potassium Chloride | Potassium Chloride | 132 | 34 |
| Metformin Hcl Er | Metformin Hcl | 129 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 59 |
| Farxiga | Dapagliflozin Propanediol | 116 | 33 |
| Prednisone | Prednisone | 116 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 30 |
| Allopurinol | Allopurinol | 113 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 35 |
| Buspirone Hcl | Buspirone Hcl | 108 | 23 |
| Carvedilol | Carvedilol | 105 | 35 |
| Pregabalin | Pregabalin | 105 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 25 |
| Famotidine | Famotidine | 91 | 29 |
| Sertraline Hcl | Sertraline Hcl | 90 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Mounjaro | Tirzepatide | 73 | 14 |
| Spironolactone | Spironolactone | 73 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Bumetanide | Bumetanide | 68 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 13 |
| Warfarin Sodium | Warfarin Sodium | 64 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 16 |
| Glimepiride | Glimepiride | 62 | 17 |
| Atenolol | Atenolol | 60 | 16 |
| Finasteride | Finasteride | 60 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 17 |
| Xarelto | Rivaroxaban | 55 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Azelastine Hcl | Azelastine Hcl | 47 | 25 |
| Januvia | Sitagliptin Phosphate | 46 | 13 |
| Ibuprofen | Ibuprofen | 40 | 19 |
| Invokana | Canagliflozin | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Colchicine | Colchicine | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 38 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 14 |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | 11 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Metolazone | Metolazone | 19 | 12 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.76 · 1 records | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Takeda Pharmaceuticals U.S.A., Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error